Cancer

October 4, 2019

Probiotic-based Chemotherapy (PCT) targeting cancer stem cells and immune-inhibitory receptors in advanced breast cancer and in other advanced metastatic cancers: A pharmaceutical mixture encompassing Palbociclib, Letrozole and probiotic Lactobacillus rhamnosus increases the expression of tumor suppressor genes, such as PDCD4, ACAT1, p53, and TA-p73/p63, inhibits immune-inhibitory receptors/molecules, targets cancer stem cells, confers protection against chemoresistance and prolongs survival, and stalls advanced breast cancer progression, via up-regulation of its target gene, 5/October/2019, 1.00 am

Probiotic-based Chemotherapy (PCT) targeting cancer stem cells and immune-inhibitory receptors in advanced breast cancer and in other advanced metastatic cancers: A pharmaceutical mixture encompassing Palbociclib, Letrozole and probiotic Lactobacillus rhamnosus increases the expression of tumor suppressor genes, such as PDCD4, ACAT1, p53, and TA-p73/p63, inhibits immune-inhibitory receptors/molecules, targets cancer stem cells, confers protection against chemoresistance and prolongs survival, and stalls advanced breast cancer progression, via up-regulation of its target gene, 5/October/2019, 1.00 am https://genomediscovery.org/wp-content/uploads/2019/10/Palbociclib-and-Letrozole-function-as-an-antitumor-agent-by-increasing-PDCD4-ACAT6.jpg 1280 720 Dr Boomi's Genom-2-Discovery Center Dr Boomi's Genom-2-Discovery Center https://genomediscovery.org/wp-content/uploads/2019/10/Palbociclib-and-Letrozole-function-as-an-antitumor-agent-by-increasing-PDCD4-ACAT6.jpg October 4, 2019 October 5, 2019

Introduction: What they say A study from Department of Medicine, Division of Hematology and Oncology, David Geffen School of Medicine at the University of California, Los Angeles, Santa Monica, the…

September 19, 2019

Probiotic-based Chemotherapy (PCT) targeting cancer stem cells and immune-inhibitory receptors in metastatic breast cancer and in other advanced metastatic cancers: A pharmaceutical mixture encompassing Palbociclib, Fulvestrant and probiotic Lactobacillus rhamnosus increases the expression of tumor suppressor genes, such as TPM1 and CADM1/2, p53, and TA-p73/p63, inhibits immune-inhibitory receptors/molecules, targets cancer stem cells, confers protection against chemoresistance and prolongs survival, and stalls metastatic breast cancer progression, via up-regulation of its target gene, 19/September/2019, 10.29 pm

Probiotic-based Chemotherapy (PCT) targeting cancer stem cells and immune-inhibitory receptors in metastatic breast cancer and in other advanced metastatic cancers: A pharmaceutical mixture encompassing Palbociclib, Fulvestrant and probiotic Lactobacillus rhamnosus increases the expression of tumor suppressor genes, such as TPM1 and CADM1/2, p53, and TA-p73/p63, inhibits immune-inhibitory receptors/molecules, targets cancer stem cells, confers protection against chemoresistance and prolongs survival, and stalls metastatic breast cancer progression, via up-regulation of its target gene, 19/September/2019, 10.29 pm https://genomediscovery.org/wp-content/uploads/2019/09/Palbociclib-Fulvestrant-functions-as-an-antitumor-agent-through-induction-of-TPM1-CADM1.2-and-others.jpg 1280 720 Dr Boomi's Genom-2-Discovery Center Dr Boomi's Genom-2-Discovery Center https://genomediscovery.org/wp-content/uploads/2019/09/Palbociclib-Fulvestrant-functions-as-an-antitumor-agent-through-induction-of-TPM1-CADM1.2-and-others.jpg September 19, 2019 September 19, 2019

Introduction: What they say A study from Institute of Cancer Research and Royal Marsden Hospital, London, David Geffen School of Medicine at University of California, Los Angeles, Santa Monica, and Pfizer Oncology,…

September 1, 2019

Probiotic-based Chemotherapy (PCT) targeting cancer stem cells and immune-inhibitory receptors in metastatic breast cancer and in other advanced metastatic cancers: A pharmaceutical mixture encompassing Abemaciclib, Metformin and probiotic Lactobacillus rhamnosus increases the expression of tumor suppressor genes, such as TPM1 and CADM1/2, p53, and TA-p73/p63, inhibits immune-inhibitory receptors/molecules, targets cancer stem cells, confers protection against chemoresistance and prolongs survival, and stalls metastatic breast cancer, via up-regulation of its target gene, 1/September/2019, 1.55 pm

Probiotic-based Chemotherapy (PCT) targeting cancer stem cells and immune-inhibitory receptors in metastatic breast cancer and in other advanced metastatic cancers: A pharmaceutical mixture encompassing Abemaciclib, Metformin and probiotic Lactobacillus rhamnosus increases the expression of tumor suppressor genes, such as TPM1 and CADM1/2, p53, and TA-p73/p63, inhibits immune-inhibitory receptors/molecules, targets cancer stem cells, confers protection against chemoresistance and prolongs survival, and stalls metastatic breast cancer, via up-regulation of its target gene, 1/September/2019, 1.55 pm https://genomediscovery.org/wp-content/uploads/2019/09/A-pharma-mix-Abemacicilip-and-metformin-increases-TPM1-and-CADM1-and-att.-tumor-progression5.jpg 1280 720 Dr Boomi's Genom-2-Discovery Center Dr Boomi's Genom-2-Discovery Center https://genomediscovery.org/wp-content/uploads/2019/09/A-pharma-mix-Abemacicilip-and-metformin-increases-TPM1-and-CADM1-and-att.-tumor-progression5.jpg September 1, 2019 September 1, 2019

Introduction: What they say A study from the Laboratory of Systems Pharmacology (at the Blavatnik Institute), Department of Systems Biology, Harvard Medical School, Boston, MA 02115, USA; and Termeer Center for…

August 30, 2019

Probiotic-based Chemotherapy (PCT) targeting cancer stem cells and immune-inhibitory receptors in relapsed chronic lymphocytic leukemia (CLL) and in advanced metastatic cancers: A pharmaceutical mixture encompassing Acalabrutinib, and probiotic Lactobacillus rhamnosus increases the expression of tumor suppressor genes, such as PPP2R2A, HDAC8, p53, and TA-p73/p63, inhibits immune-inhibitory receptors/molecules, targets cancer stem cells, confers protection against chemoresistance and prolongs survival, and stalls CLL progression, via up-regulation of its target gene, 30/August/2019, 10.22 pm

Probiotic-based Chemotherapy (PCT) targeting cancer stem cells and immune-inhibitory receptors in relapsed chronic lymphocytic leukemia (CLL) and in advanced metastatic cancers: A pharmaceutical mixture encompassing Acalabrutinib, and probiotic Lactobacillus rhamnosus increases the expression of tumor suppressor genes, such as PPP2R2A, HDAC8, p53, and TA-p73/p63, inhibits immune-inhibitory receptors/molecules, targets cancer stem cells, confers protection against chemoresistance and prolongs survival, and stalls CLL progression, via up-regulation of its target gene, 30/August/2019, 10.22 pm https://genomediscovery.org/wp-content/uploads/2019/08/Acalabrutinib-attenuates-tumor-prog-through-induction-of-HDAC8-and-PPP2R2A5.jpg 1280 720 Dr Boomi's Genom-2-Discovery Center Dr Boomi's Genom-2-Discovery Center https://genomediscovery.org/wp-content/uploads/2019/08/Acalabrutinib-attenuates-tumor-prog-through-induction-of-HDAC8-and-PPP2R2A5.jpg August 30, 2019 August 30, 2019

Introduction: What they say A study from the the Division of Hematology, Department of Internal Medicine, Ohio State University, and the Department of Veterinary Biosciences, College of Veterinary Medicine –…

August 23, 2019

Probiotic-based Chemotherapy (PCT) targeting cancer stem cells and immune-inhibitory receptors in relapsed chronic lymphocytic leukemia (CLL) and in advanced metastatic cancers: A pharmaceutical mixture encompassing Acalabrutinib, and probiotic Lactobacillus rhamnosus increases the expression of tumor suppressor genes, such as PDCD4, ACAT1, p53, and TA-p73/p63, inhibits immune-inhibitory receptors/molecules, targets cancer stem cells, confers protection against chemoresistance and prolongs survival, and stalls CLL progression, via up-regulation of its target gene, 23/August/2019, 10.39 pm

Probiotic-based Chemotherapy (PCT) targeting cancer stem cells and immune-inhibitory receptors in relapsed chronic lymphocytic leukemia (CLL) and in advanced metastatic cancers: A pharmaceutical mixture encompassing Acalabrutinib, and probiotic Lactobacillus rhamnosus increases the expression of tumor suppressor genes, such as PDCD4, ACAT1, p53, and TA-p73/p63, inhibits immune-inhibitory receptors/molecules, targets cancer stem cells, confers protection against chemoresistance and prolongs survival, and stalls CLL progression, via up-regulation of its target gene, 23/August/2019, 10.39 pm https://genomediscovery.org/wp-content/uploads/2019/08/Acalabrutinib-attenuates-tumor-progression-through-indcution-of-PDCD4-and-ACAT1.jpg 1280 720 Dr Boomi's Genom-2-Discovery Center Dr Boomi's Genom-2-Discovery Center https://genomediscovery.org/wp-content/uploads/2019/08/Acalabrutinib-attenuates-tumor-progression-through-indcution-of-PDCD4-and-ACAT1.jpg August 23, 2019 August 23, 2019

August 16, 2019

Probiotic-based chemotherapy targeting cancer stem cells and immune-inhibitory receptors in chronic lymphocytic leukemia (CLL) and in advanced metastatic cancers: A pharmaceutical mixture encompassing Venetoclax and Ibrutinib (VAI) and probiotic Lactobacillus rhamnosus increases the expression of tumor suppressor genes, such as VHL1, TET1, p53, and TA-p73/p63, inhibits immune-inhibitory receptors/molecules, targets cancer stem cells, confers protection against chemoresistance and prolongs survival, and stalls CLL progression, via up-regulation of its target gene, 16/August/2019, 10.08 pm

Probiotic-based chemotherapy targeting cancer stem cells and immune-inhibitory receptors in chronic lymphocytic leukemia (CLL) and in advanced metastatic cancers: A pharmaceutical mixture encompassing Venetoclax and Ibrutinib (VAI) and probiotic Lactobacillus rhamnosus increases the expression of tumor suppressor genes, such as VHL1, TET1, p53, and TA-p73/p63, inhibits immune-inhibitory receptors/molecules, targets cancer stem cells, confers protection against chemoresistance and prolongs survival, and stalls CLL progression, via up-regulation of its target gene, 16/August/2019, 10.08 pm https://genomediscovery.org/wp-content/uploads/2019/08/Venetoclax-and-Ibrutinib-atenuate-tumor-progression-through-induciton-of-VHL1-and-TET14.jpg 1280 720 Dr Boomi's Genom-2-Discovery Center Dr Boomi's Genom-2-Discovery Center https://genomediscovery.org/wp-content/uploads/2019/08/Venetoclax-and-Ibrutinib-atenuate-tumor-progression-through-induciton-of-VHL1-and-TET14.jpg August 16, 2019 August 16, 2019

Introduction: What they say A study from the University of Texas M.D. Anderson Cancer Center, Houston, USA shows that “Ibrutinib and Venetoclax for First-Line Treatment of CLL.” This research paper was published, in…

Popular Post